Prognostic factor analysis of health-related quality of life data in cancer: A statistical methodological evaluation

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 2, 2008, Pages 179-196

  Mauer, Murielle E ^a   Bottomley, Andrew ^a   Coens, Corneel ^a   Gotay, Carolyn ^b  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Patient reported outcomes; Prognostic factors; Quality of life; Survival

Indexed keywords

CANCER CLASSIFICATION; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CORRELATION ANALYSIS; DISEASE COURSE; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; MEDICAL LITERATURE; MORTALITY; PATIENT ATTITUDE; PREDICTION; PROGNOSIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SELF REPORT; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 46949109816     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.2.179     Document Type: Review

References (68)

1. Velikova G, Booth L, Smith AB et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J. Clin. Oncol. 22(4), 714-724 (2004).
2. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 288(23), 3027-3034 (2002).
3. Bottomley A, Vanvoorden V, Flechtner H, Therasse P. The challenge and achievements of implementation of quality of life research in cancer clinical trials. Eur. J. Cancer 39, 275-285 (2003).
4. Efficace F, Biganzoli L, Piccart M et al. Baseline health-related quality-of-life data as prognostic factors in a Phase III multicentre study of women with metastatic breast cancer. Eur. J. Cancer 40(7), 1021-1030 (2004).
5. Bottomley A, Flechtner H, Efficace F et al. Health related quality of life outcomes in cancer clinical trials. Eur. J. Cancer 41, 1697-1709 (2005).
6. Kam S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother. Oncol. 15(3), 235-242 (1989).
7. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31(2-3), 233-240 (2001).
8. Herndon JE II, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 85(2), 333-340 (1999).
9. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother. Oncol. 55, 19-25 (2000).
10. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 58, 1394-1404 (2004).
11. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49, 227-230 (2001).
12. Luoma ML, Hakamies-Blomqvist L, Sjöström J et al. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur. J. Cancer 39(10), 1370-1376 (2003).
13. Coates A, Thomson D, McLeod GR et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur. J. Cancer 29A, 1731-1734 (1993).
14. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J. Clin. Oncol. 21(4), 673-678 (2003).
15. de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur. J. Cancer 37, 332-339 (2001).
16. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol. 26(8), 1355-1363 (2008).
17. Coates AS, Humy C, Peterson HF et al. Quality-of-fife scores predict outcome in metastatic but not early breast cancer. J. Clin. Oncol. 18, 3768-3774 (2000).
18. Harrell FE, Lee KL, Mark DB. Tutorial in Biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist. Med. 15, 361-387 (1996).
19. Fielding R, Wong WS. Quality of life as predictor of cancer survival among Chinese liver and lung cancer patients. Eur. J. Cancer 43(11), 1723-1730 (2007).
20. Gripp S, Moeller S, Bölke E et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J. Clin. Oncol. 25(22), 3313-3320 (2007).
21. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu-Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom. Res. 63(1), 9-15 (2007).
22. Martins SJ, Ho N, Cavamura SO, Harada CM, Yamamoto CA, Takagaki TY. Lung cancer symptoms and pulse oximetry in the prognostic assessment of patients with lung cancer. BMC Cancer 5(1), 72 (2005).
23. McCarter H, Furlong W, Whitton AC et al. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. J. Clin. Oncol. 24(22), 3636-3643 (2006).
24. Park SM, Park MH, Won JH et al. EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units. Support. Care Cancer 14(4), 329-333 (2006).
25. Teunissen SC, de Graeff A, de Haes HC, Voest EE. Prognostic significance of symptoms of hospitalized advanced cancer patients. Eur. J. Cancer 42(15), 2510-2516 (2006).
26. Fossa SD, Paus E, Lindegaard M, Newling DW. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br. J. Urol. 69(2), 175-179 (1992).
27. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med. Oncol. 18(1), 85-94 (2001).
28. Loprinzi CL, Laurie JA, Wieand HS et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin. Oncol. 12(3), 601-607 (1994).
29. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur. Arch. Psychiatry Clin. Neurosci. 256(8), 516-521 (2006).
30. Serkalem D, LaValley MP Horton NJ, Glynn RJ, Cupples LA. Bias due to missing exposure data using complete-case analysis in the proportional hazards regression model. Statist. Med. 22, 545-557 (2003).
31. Barzi F, Woodward M. Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies. Am. J. Epidemiol. 160, 34-45 (2004).
32. Leong T, Lipsitz SR, Ibrahim JG. Incomplete covariates in the Cox model with applications to biological marker data. J. Roy. Statist. Soc. Ser. C (Appl. Stat.) 50(4), 467-484 (2001).
33. Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of life outcome from a randomized Phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23(21), 4617-4625 (2005).
34. Naughton MJ, Herndon JE II, Shumaker SA et al. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual. Life Res. 11(3), 235-248 (2002).
35. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12), 3131-3135 (1991).
36. Chiarion-Sileni V, Del Bianco P, De Salvo GL et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur. J. Cancer 39(11), 1577-1585 (2003).
37. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Statist. Med 25, 127-141 (2006).
38. Mauer M, Taphoorn MJB, Bottomley A et al. The prognostic value of health-related quality of life data in predicting survival in anaplastic oligodendrogliomas cancer patients: results from an international randomized Phase III EORTC Brain Cancer Group study. J. Clin. Oncol. 25(36), 5731-5737 (2007).
39. Mauer M, Stupp R, Taphoom MJ et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised Phase III EORTC Brain Tumor and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br. J. Cancer 97(3), 302-307 (2007).
40. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl Cancer Inst. 86(11), 829-835 (1994).
41. Dancey J, Zee B, Osoba D et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual. Life Res. 6(2), 151-158 (1997).
42. Tross S, Herndon J II, Korzun A et al. Psychological symptoms and disease-fice and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J. Natl Cancer Inst. 88(10), 661-667 (1996).
43. Coates A, Gebski V, Signorini D et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J. Clin. Oncol. 10(12), 1833-1838 (1992).
44. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996).
45. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J. Clin. Oncol. 18(3), 646-650 (2000).
46. Kramer JA, Curran D, Piccart M et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur. J. Cancer 36 (12), 1498-1506 (2000).
47. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. Chest 106(6 Suppl.), S324-S328 (1994).
48. Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual. Life Res. 15(8), 1297-1306 (2006).
49. Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 22(11), 2061-2068 (2004).
50. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European organization for research and treatment of cancer core quality of life questionnaire and lung cancer module. J. Clin. Oncol. 22(15), 3172-3180 (2004).
51. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur. J. Cancer 38(10), 1351-1357 (2002).
52. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 22(12), 2395-2403 (2004).
53. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J. Clin. Oncol. 21(8), 1536-1543 (2003).
54. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study. J. Clin. Oncol. 23(28), 6865-6872 (2005).
55. Collette L, Van Andel G, Bottomley A et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 22(19), 3877-3885 (2004).
56. Brown PD, Ballman KV, Rummans TA et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J. Neurooncol. 76(3), 283-291 (2006).
57. Efficace F, Therasse P, Piccart MJ et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J. Clin. Oncol. 22(16), 3381-3388 (2004).
58. Efficace F, Bottomley A, Coens C et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur. J. Cancer 42(1), 42-49 (2006).
59. Efficace F, Bottomley A, Smit EF et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann. Oncol. 17(11), 1698-1704 (2006).
60. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Statist. Med. 11, 2093-2109 (1992).
61. Van Steen K, Curran D, Kramer J et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model. Stat. Med. 21(24), 3865-3884 (2002).
62. Ferrans CE. Definitions and conceptual models of quality of life. In: Outcomes Assessment in Cancer: Measures, Methods, and Applications. Gotay CC, Lipscomb J, Snyder C (Eds). Cambridge University Press, Cambridge, England, UK, 14-30 (2005).
63. Seidman AD, Portenoy R, Yao TJ et al. Quality of life in Phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst. 87(17), 1316-1322 (1995).
64. Yeo W, Mo FK, Koh J et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann. Oncol. 17(7), 1083-1089 (2006).
65. Brown J, Thorpe H, Napp V et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J. Clin. Oncol. 23(30), 7417-7427 (2005).
66. Moinpour CM, Lyons B, Grevstad PK et al. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual. Life Res. 11(2), 115-126 (2002).
67. Dubois D, Dhawan R, van de Velde H et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J. Clin. Oncol. 24(6), 976-982 (2006).
68. Wisloff F, Hjorth M. Health-related quality of fife assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br. J. Haematol. 97(1), 29-37 (1997).